Michael Thomas Hoffmann, EVP and General Counsel of NXP Semiconductors N.V. (NASDAQ:NXPI), filed a Form 4 on November 9, 2026, disclosing restricted stock unit vestings and related share withholdings on November 5 and November 7, 2026.
Rafael Sotomayor, CEO and President of NXP Semiconductors N.V. (NASDAQ:NXPI), filed a Form 4 on November 9, 2026, disclosing restricted stock unit vestings and related share disposals on November 5 and November 7, 2026.
Andrew Hardy, EVP and Chief Sales Officer of NXP Semiconductors N.V. (NASDAQ:NXPI), filed a Form 4 on November 9, 2026, disclosing restricted stock unit vesting events and related share withholdings on November 5 and November 7, 2026.
Neil B. Shah, Chief Commercial Officer of SharkNinja, Inc. (NYSE:SN), filed a Form 4 on November 9, 2026, disclosing the sale of ordinary shares on November 6, 2026, held indirectly through a limited partnership.
Director Anthony R. Foxx filed a Form 4 with the SEC on November 9, 2026, disclosing a charitable gift of 85 shares of NXP Semiconductors N.V. common stock made on November 5, 2026.
NXP Semiconductors N.V. EVP and CFO William Betz filed a Form 4 on November 9, 2026, disclosing two restricted stock unit vesting events and related tax-withholding disposals of common stock on November 5 and November 7, 2026.
Shereen Solaiman, Chief People Officer of Myriad Genetics Inc, filed a statement of changes in beneficial ownership on November 9, 2026, disclosing a grant of 83,049 time-based stock options on November 6, 2026.
Benjamin Richard Wheeler, Chief Financial Officer of Myriad Genetics Inc, filed a Form 4 on November 9, 2026, disclosing the acquisition of a time-based stock option covering 121,379 shares of common stock granted on November 6, 2026.
Myriad Genetics Inc Chief Operating Officer Mark Verratti filed a Form 4 on November 9, 2026, disclosing the acquisition of 146,933 time-based stock options granted on November 6, 2026, as a retention award under the company's 2026 Employee, Director and Consultant Equity Incentive Plan.
Dale Muzzey, Chief Scientific Officer of Myriad Genetics Inc, filed a Form 4 on November 9, 2026, disclosing the acquisition of 92,632 time-based stock options granted as a one-time retention award on November 6, 2026.